For example, one clinical study saw no clinical efficacy in recurrent glioblastoma patients cotreated with CAR T-cell therapy targeting epidermal growth factor receptor (EGFR) III and the anti-PD1 antibody pembrolizumab8. The gene discussed is EGFR; the disease is glioblastoma.